Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s Clark: 2009 is a Year of Fundamental Change

Executive Summary

In 2009, Merck is implementing a new business model that fundamentally transforms the company and is crucial to its future, CEO Richard Clark told analysts at a Goldman Sachs health care conference Jan. 7

You may also be interested in...

Merck Continues Looking For The “Right” Biotech Buying Opportunity

Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.

As Sales Slip, Merck & Co. Plans 7,200 Job Cuts

Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.

Merck Commercial Model: Expand Customer Base, Tighten Marketing Spend

Merck expects to reduce its marketing spend by about 15 to 20 percent per product, Global Pharmaceuticals President Adam Schechter told the Pharmaceutical Strategic Alliances conference in New York on September 25





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts